Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB

References

• Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124(4):511–518.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037.
   PubMed Web of Science ®Google Scholar
• Smith BD. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects. J Natl Cancer Inst. 2011;103(7):527–529.
   PubMedGoogle Scholar
• Jain P, Kantarjian H, Cortes J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol. 2013;14(2):127–143.
   PubMed Web of Science ®Google Scholar
• Bhamidipati PK, Kantarjian H, Cortes J, et al. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013;4(2):103–117.
   PubMedGoogle Scholar
• Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 2015;16(7):421–433.
   PubMed Web of Science ®Google Scholar
• Barbato S, Solaini G, Fabbri M. microRNAs in oncogenesis and tumor suppression. Int Rev Cell Mol Biol. 2017;333:229–268.
   PubMed Web of Science ®Google Scholar
• Vannini I, Fanini F, Fabbri M. Emerging roles of microRNAs in cancer. Curr Opin Genet Dev. 2018;48:128–133.
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–469.
   PubMed Web of Science ®Google Scholar
• Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008;7(1):1–9.
   PubMed Web of Science ®Google Scholar
• Farhadi E, Zaker F, Safa M, et al. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-kappaB target genes. Tumour Biol. 2016;37(10):14117–14128.
   PubMedGoogle Scholar
• Nie ZY, Yao M, Yang Z, et al. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance. J Exp Clin Cancer Res. 2020;39(1):17.
   PubMed Web of Science ®Google Scholar
• Meenakshi Sundaram DN, Jiang X, Brandwein JM, et al. Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. Drug Discov Today. 2019;24(7):1355–1369.
   PubMed Web of Science ®Google Scholar
• Han Z, Zhou X, Li S, et al. Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway. Oncol Rep. 2017;38(5):3064–3070.
   PubMed Web of Science ®Google Scholar
• Shang J, Yang F, Wang Y, et al. MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells. J Cell Biochem. 2014;115(4):772–784.
   PubMed Web of Science ®Google Scholar
• Peng F, Zhang H, Du Y, et al. miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through twist. Oncol Rep. 2015;33(2):942–950.
   PubMed Web of Science ®Google Scholar
• Xishan Z, Xianjun L, Ziying L, et al. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chronic myeloid leukemia. Cancer Gene Ther. 2014;21(9):397–404.
   PubMed Web of Science ®Google Scholar
• Eide CA, Druker BJ. Understanding cancer from the stem cells up. Nat Med. 2017;23(6):656–657.
   PubMed Web of Science ®Google Scholar
• Zhou H, Mak PY, Mu H, et al. Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017;31(10):2065–2074.
   PubMed Web of Science ®Google Scholar
• Kurkewich JL, Hansen J, Klopfenstein N, et al. The miR-23a~27a~24-2 microRNA cluster buffers transcription and signaling pathways during hematopoiesis. PLoS Genet. 2017;13(7):1006887.
   Web of Science ®Google Scholar
• Hu X, Wang Y, Liang H, et al. miR-23a/b promote tumor growth and suppress apoptosis by targeting PDCD4 in gastric cancer. Cell Death Dis. 2017;8(10):e3059.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Tao Y, Zhang X, et al. Loss of STAT5A promotes glucose metabolism and tumor growth through miRNA-23a-AKT signaling in hepatocellular carcinoma. Mol Oncol. 2021;15(2):710–724.
   PubMed Web of Science ®Google Scholar
• Hatzl S, Perfler B, Wurm S, et al. Increased expression of micro-RNA-23a mediates chemoresistance to cytarabine in acute myeloid Leukemia. Cancers (Basel). 2020;12(2). DOI:10.3390/cancers12020496.
   PubMed Web of Science ®Google Scholar
• Wang G, Li B, Fu Y, et al. miR-23a suppresses proliferation of osteosarcoma cells by targeting SATB1. Tumour Biol. 2015;36(6):4715–4721.
   PubMedGoogle Scholar
• Ma M, Dai J, Tang H, et al. MicroRNA-23a-3p inhibits mucosal melanoma growth and progression through targeting adenylate cyclase 1 and attenuating cAMP and MAPK pathways. Theranostics. 2019;9(4):945–960.
   PubMed Web of Science ®Google Scholar
• Ganesan S, Palani HK, Lakshmanan V, et al. Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia. Cell Death Dis. 2019;10(10):736.
   PubMed Web of Science ®Google Scholar
• Sreekumar PG, Kannan R, Kitamura M, et al. alphaB crystallin is apically secreted within exosomes by polarized human retinal pigment epithelium and provides neuroprotection to adjacent cells. PLoS One. 2010;5(10):12578.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu J, Wu J, et al. Progression of the role of CRYAB in signaling pathways and cancers. Onco Targets Ther. 2019;12:4129–4139.
   PubMed Web of Science ®Google Scholar
• Wang SN, Luo S, Liu C, et al. miR-491 inhibits osteosarcoma lung metastasis and chemoresistance by targeting alphaB-crystallin. Mol Ther. 2017;25(9):2140–2149.
   PubMed Web of Science ®Google Scholar
• Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer. 2015;113(4):569–573.
   PubMed Web of Science ®Google Scholar
• Zebisch A, Hatzl S, Pichler M, et al. Therapeutic resistance in acute myeloid leukemia: the role of non-coding RNAs. Int J Mol Sci. 2016;17(12). DOI:10.3390/ijms17122080
   PubMed Web of Science ®Google Scholar
• Lu B, Sheng Y, Zhang J, et al. The altered microRNA profile in andrographolide-induced inhibition of hepatoma tumor growth. Gene. 2016;588(2):124–133.
   PubMed Web of Science ®Google Scholar
• Wang N, Zhu M, Wang X, et al. Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta. 2014;1839(9):849–857.
   PubMed Web of Science ®Google Scholar
• Bamodu OA, Kuo KT, Yuan LP, et al. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. Exp Cell Res. 2018;370(2):519–530.
   PubMed Web of Science ®Google Scholar